SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 654.74-0.5%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotechwantabe who wrote (3016)6/27/2020 5:42:41 AM
From: Biotechwantabe1 Recommendation

Recommended By
CuttingEdge Bio

   of 3557
 
verywellhealth.com

EGFR and Squamous Cell Carcinoma of the Lungs The EGFR pathway may also be targeted for people with squamous cell carcinoma of the lungs who do not have EGFR mutations.

Instead of an EGFR mutation driving these cancers, growth is instead related to EGFR amplification. And instead of using tyrosine kinase inhibitors to target an EGFR mutation, anti-EGFR antibodies bind to EGFR on the outside of the cell (in cancers which do not have an EGFR mutation) to interrupt the signaling pathway.15?

Portrazza (necitumumab) was approved in 2015 along with chemotherapy for people with advanced squamous cell carcinoma of the lungs who have not received prior treatment. Portrazza is a monoclonal antibody (man-made antibody) that blocks the activity of EGFR.16? Anti-EGFR antibody therapy drugs—such as the medications Erbitux (cetuximab) and Vectibix (panitumumab)—have been used with other cancers as well.17?

Unlike the drugs used for adenocarcinoma above which are given orally, the anti-EGFR therapy drug Portrazza is given intravenously.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News